Psychedelikagestützte Psychotherapie in der Behandlung depressiver Störungen

ZUSAMMENFASSUNG

In den letzten Jahren wurde ein Anstieg depressiver Erkrankungen innerhalb der deutschen Bevölkerung verzeichnet [1]. Dabei sprechen ca. 30 % der Patienten nicht ausreichend auf die Behandlung mit verschiedenen Antidepressiva an und gelten somit als therapieresistent [2]. Psychedelika wie Psilocybin stellen einen vielversprechenden Therapieansatz in der Behandlung der Depression dar. Der Einsatz von Psychedelika in Therapie und Forschung wurde Anfang der 1970er-Jahre durch die Eingruppierung als Betäubungsmittel stark erschwert und ist erst in den 1990er-Jahren wieder aufgenommen worden.

In diesem Artikel wird der Stand der Forschung zur psychedelikaassistierten Psychotherapie vorgestellt. Ein besonderes Augenmerk wird dabei auf die Forschung zu psychedelikagestützter Psychotherapie bei depressiven Störungen gelegt, gefolgt von einem Ausblick.

ABSTRACT

Over the past years, the number of depressive disorders amongst the German population has risen [1]. Approximately 30 % of patients treated with antidepressants do not show adequate treatment response and are diagnosed as therapy-resistant [2]. Psychedelics such as psilocybin represent a promising therapeutic approach in the treatment of depression. Treatment and clinical research with psychedelics was hampered since the 1970ies due to classification as schedule-I-substances, and was resumed only from the 1990ies on.

This article reviews the state of research on psychedelic-assisted therapy. Special attention is given to research on psychedelic-assisted psychotherapy for depression, followed by an outlook.

Schlüsselwörter

Therapieresistente Depression - psychedelikaassistierte Psychotherapie - psilocybingestützte Psychotherapie

Key words

Therapy-resistant depression - psychedelic-assisted psychotherapy - psilocybin

Publication History

Article published online:
07 July 2023

• Literatur

• 1 Busch M, Maske U, Ryl L. et al Prävalenz von depressiver Symptomatik und diagnostizierter Depression bei Erwachsenen in Deutschland. 2013. Berlin: RKI;
• 2 Ludwig W-D, Mühlbauer B, Seifert R. Arzneiverordnungs-Report 2021. Berlin: Springer; 2021
• 3 Nichols DE. Chemistry and structure-activity relationships of psychedelics. Behavioral Neurobiology of Psychedelic Drugs 2018: 1-43
• 4 Amoroso T, Workman M. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: a preliminary meta-analysis and comparison to prolonged exposure therapy. Journal of Psychopharmacology 2016; 30: 595-600
• 5 Papakostas GI, Salloum NC, Hock RS. et al Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. The Journal of clinical psychiatry 2020; 81: 6603
• 6 Bisbee CC, Bisbee P, Dyck E. et al Psychedelic Prophets: The Letters of Aldous Huxley and Humphry Osmond. New York: McGill-Queen’s Press-MQUP; 2018
• 7 Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. Journal of psychopharmacology 2008; 22: 603-620
• 8 Ulrich RF, Patten BM. The rise, decline, and fall of LSD. Perspectives in Biology and Medicine 1991; 34: 561-578
• 9 Grinspoon L, Bakalar JB. Psychedelic drugs reconsidered. New York: Basic Books; 1979
• 10 Sandison RA. Psychological aspects of the LSD treatment of the neuroses. Journal of Mental Science 1954; 100: 508-515
• 11 Chwelos N, Blewett D, Smith CM. et al Use of d-lysergic acid diethylamide in the treatment of alcoholism. Quarterly journal of studies on alcohol 1959; 20: 577-590
• 12 Ludwig A, Levine J, Stark L. et al A clinical study of LSD treatment in alcoholism. American Journal of Psychiatry 1969; 126: 59-69
• 13 Kurland A, Savage C, Pahnke WN. et al LSD in the treatment of alcoholics. Pharmacopsychiatry 1971; 04: 83-94
• 14 Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study. Archives of General Psychiatry 1973; 28: 808-814
• 15 Savage C. Lysergic acid diethylamide (LSD-25) A clinical-psychological study. American Journal of Psychiatry 1952; 108: 896-900
• 16 Fernberger SW. Further observations on peyote intoxication. The Journal of Abnormal and Social Psychology 1932; 26: 367
• 17 Fernberger SW. Observations on Taking Peyote”(Anhalonium Lewinii)”. The American Journal of Psychology 1923; 34: 267-270
• 18 Guttmann E, Maclay W. Mescalin and depersonalization: therapeutic experiments. Journal of Neurology and Psychopathology 1936; 16: 193
• 19 Hofmann A. Psychotomimetic drugs. Acta physiologica et pharmacologica Neerlandica 1959; 08: 240-258
• 20 Aresin L. Modellpsychosen. Psychiatrie, Neurologie und medizinische Psychologie 1960; 12: 94-99
• 21 Aday JS, Bloesch EK, Davoli CC. Beyond LSD: a broader psychedelic zeitgeist during the early to mid-20th century. Journal of Psychoactive Drugs 2019; 51: 210-217
• 22 Johansen P-Ø, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of psychopharmacology 2015; 29: 270-279
• 23 Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A. et al Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998; 09: 3897-3902
• 24 Strassman RJ, Qualls CR. Dose-response study of N, N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects. Archives of general psychiatry 1994; 51: 85-97
• 25 Strassman RJ, Qualls CR, Uhlenhuth EH. et al Dose-response study of N, N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale. Archives of general psychiatry 1994; 51: 98-108
• 26 Griffiths RR, Richards WA, McCann U. et al Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006; 187: 268-283
• 27 Hasler F, Grimberg U, Benz MA. et al Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study. Psychopharmacology 2004; 172: 145-156
• 28 Grob CS, Danforth AL, Chopra GS. et al Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of general psychiatry 2011; 68: 71-78
• 29 Ross S, Bossis A, Guss J. et al Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of psychopharmacology 2016; 30: 1165-1180
• 30 Griffiths RR, Johnson MW, Carducci MA. et al Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology 2016; 30: 1181-1197
• 31 Gasser P, Holstein D, Michel Y. et al Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of nervous and mental disease 2014; 202: 513
• 32 Bogenschutz MP, Ross S. Therapeutic applications of classic hallucinogens. Behavioral neurobiology of psychedelic drugs 2018: 361-391
• 33 Koslowski M, Johnson MW, Gründer G. et al Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports 2022: 1-11
• 34 Horton DM, Morrison B, Schmidt J. Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy. American journal of psychotherapy 2021; 74: 140-149
• 35 Johnson MW, Garcia-Romeu A, Cosimano MP. et al Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of psychopharmacology 2014; 28: 983-992
• 36 Bogenschutz MP, Forcehimes AA, Pommy JA. et al Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of psychopharmacology 2015; 29: 289-299
• 37 Passie T, Seifert J, Schneider U. et al The pharmacology of psilocybin. Addiction biology 2002; 07: 357-364
• 38 Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug metabolism reviews 2017; 49: 84-91
• 39 Hasler F, Bourquin D, Brenneisen R. et al Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharmaceutica Acta Helvetiae 1997; 72: 175-184
• 40 Furukawa TA, Cipriani A, Cowen PJ. et al Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. The Lancet Psychiatry 2019; 06: 601-609
• 41 Carhart-Harris RL, Bolstridge M, Rucker J. et al Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry 2016; 03: 619-627
• 42 Davis AK, Xin Y, Sepeda ND. et al Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chronic Stress 2021; 5: 24705470211035607
• 43 Gukasyan N, Davis AK, Barrett FS. et al Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. Journal of Psychopharmacology 2022; 36: 151-158
• 44 Sanches RF, de Lima Osório F, Dos Santos RG. et al Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. Journal of clinical psychopharmacology 2016; 36: 77-81
• 45 Palhano-Fontes F, Barreto D, Onias H. et al Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological medicine 2019; 49: 655-663
• 46 Carhart-Harris R, Giribaldi B, Watts R. et al Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 2021; 384: 1402-1411
• 47 Nayak SM, Bari BA, Yaden DB. et al A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression. Psychedelic Medicine 2023; 01: 18-26
• 48 Goodwin GM, Aaronson ST, Alvarez O. et al Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine 2022; 387: 1637-1648
• 49 Ko K, Knight G, Rucker JJ. et al Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Frontiers in psychiatry 2022: 13
• 50 Mueller F, Lenz C, Dolder P. et al Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Translational psychiatry 2017; 07: e1084-e1084
• 51 Kraehenmann R, Preller KH, Scheidegger M. et al Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological psychiatry 2015; 78: 572-581
• 52 Kraehenmann R. Dreams and psychedelics: neurophenomenological comparison and therapeutic implications. Current neuropharmacology 2017; 15: 1032-1042
• 53 Broyd SJ, Demanuele C, Debener S. et al Default-mode brain dysfunction in mental disorders: a systematic review. Neuroscience & biobehavioral reviews 2009; 33: 279-296
• 54 Carhart-Harris RL, Erritzoe D, Williams T. et al Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences 2012; 109: 2138-2143
• 55 Preller KH, Burt JB, Ji JL. et al Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife 2018; 07: e35082
• 56 Vargas MV, Dunlap LE, Dong C. et al Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 2023; 379: 700-706
• 57 Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology 2015; 29: 1182-1190
• 58 Carhart-Harris RL, Bolstridge M, Day CM. et al Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 2018; 235: 399-408
• 59 Davis AK, So S, Lancelotta R. et al 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American journal of drug and alcohol abuse 2019; 45: 161-169
• 60 Mertens LJ, Koslowski M, Betzler F. et al Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)–Rationale and study design. Neuroscience Applied 2022; 01: 100104
• 61 Schlag AK, Aday J, Salam I. et al Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology 2022; 36: 258-272
• 62 Breeksema JJ, Kuin BW, Kamphuis J. et al Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. Journal of Psychopharmacology 2022; 36: 1100-1117
• 63 Halpern JH, Lerner AG, Passie T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Behavioral neurobiology of psychedelic drugs 2018: 333-360
• 64 Vis PJ, Goudriaan AE, Ter Meulen BC. et al On Perception and Consciousness in HPPD: A Systematic Review. Frontiers in Neuroscience 2021; 15: 675768
• 65 Krebs TS, Johansen P-Ø.. Psychedelics and mental health: a population study. PloS one 2013; 08: e63972
• 66 Dos Santos RG, Bouso JC, Hallak JE. Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. Therapeutic advances in psychopharmacology 2017; 07: 141-157
• 67 Gashi L, Sandberg S, Pedersen W. Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. International Journal of Drug Policy 2021; 87: 102997
• 68 Hendricks PS, Thorne CB, Clark CB. et al Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology 2015; 29: 280-288
• 69 Zeifman RJ, Singhal N, Breslow L. et al On the relationship between classic psychedelics and suicidality: a systematic review. ACS Pharmacology & Translational Science 2021; 04: 436-451
• 70 Search of: Psychedelics | Recruiting NyR, Active, Not Recruiting, Enrolling by Invitation Studies | Depression – List Results – ClinicalTrials.gov, n.d.-b. clinicaltrails.gov
• 71 Mertens LJ, Preller KH. Classical psychedelics as therapeutics in psychiatry–current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders. Pharmacopsychiatry 2021; 54: 176-190
• 72 Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. The American journal of drug and alcohol abuse 2017; 43: 55-60
• 73 Osório FdL, Sanches RF, Macedo LR. et al Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Brazilian Journal of Psychiatry 2015; 37: 13-20
• 74 Chuang-Stein C, Kirby S. The shrinking or disappearing observed treatment effect. Pharmaceutical Statistics 2014; 13: 277-280
• 75 Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. The Lancet 2010; 376: 1558-1565
• 76 Zeifman RJ, Wagner AC, Watts R. et al Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Frontiers in psychiatry 2020: 782
• 77 Kelly JR, Gillan CM, Prenderville J. et al Psychedelic therapy’s transdiagnostic effects: a research domain criteria (RDoC) perspective. Frontiers in psychiatry 2021: 2295
• 78 Wolff M, Evens R, Mertens LJ. et al Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance. Frontiers in psychiatry 2020: 5